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ABSTRACT
Objective To assess if 12 novel circulating biomarkers, 
when added to ‘standard predictors’ available in general 
practice, could improve the 10- year prediction of 
cardiovascular events and mortality in patients with stable 
coronary heart disease.
Design The patients participated as placebo receiving 
patients in the randomised clarithromycin for patients 
with stable coronary artery disease (CLARICOR) trial at a 
random time in their disease trajectory.
Setting Five Copenhagen University cardiology 
departments and a coordinating centre.
Participants 1998 participants with stable coronary 
artery disease.
Outcomes Death and composite of myocardial infarction, 
unstable angina pectoris, cerebrovascular disease and 
death.
Results When only ‘standard predictors’ were 
included, 83.4% of all- cause death predictions and 
68.4% of composite outcome predictions were correct. 
Log(calprotectin) and log(cathepsin- S) were not associated 
(p≥0.01) with the outcomes, not even as single predictors. 
Adding the remaining 10 biomarkers (high- sensitive 
assay cardiac troponin T; neutrophil gelatinase- associated 
lipocalin; osteoprotegerin; N- terminal pro- B- type 
natriuretic peptide; tumour necrosis factor receptor 1 and 
2; pregnancy- associated plasma protein A; endostatin; 
YKL40; cathepsin- B), which were all individually 
significantly associated with the prediction of the two 
outcomes, increased the figures to 84.7% and 69.7%.
Conclusion When ‘standard predictors’ routinely available 
in general practices are used for risk assessment in 
consecutively sampled patients with stable coronary 
artery disease, the addition of 10 novel biomarkers to the 
prediction model improved the correct prediction of all- 
cause death and the composite outcome by <1.5%.
Trial registration number NCT00121550.
INTRODUCTION
Previously, we have studied the prognostic 
impact of routinely available ‘standard predic-
tors’ when added to a prediction model void 
of covariates using the placebo receiving 
participants from the CLARICOR trial.1–4 
The impact, however, was quite modest.1 
For risk assessment of patients with coronary 
artery disease (CAD), there are a number of 
advanced biomarkers, including several from 
outside cardiology, which may help identi-
fying CAD patients at high risk of cardiovas-
cular (CV) disease manifestations.2 Here, 
we assess the prognostic impact—relative to 
standard clinical predictors usually available 
during routine clinical work—of 12 newer 
biomarkers in predicting death and other 
serious CV events in patients suffering from 
CAD sampled while their disease was stable.
Briefly, the biomarkers are (1) serum N- ter-
minal pro- B- type natriuretic peptide (pro- 
BNP), a marker of left ventricular dysfunction 
and heart failure; (2) high- sensitive assay 
cardiac troponin T (hs- cTnT) indicating 
myocardial ischaemia; (3) YKL40 found to 
be predictive of acute myocardial infarction 
(AMI), CV death and non- CV death; (4) the 
glycoprotein osteoprotegerin (OPG), which 
is positively related to coronary calcification, 
Strengths and limitations of this study
 ► Use of multiple biomarkers.
 ► Well- established cohort.
 ► Comprehensive statistical approach.
 ► Missing external validation.
 ► Relatively old cohort.
Protected by copyright.
 o
n
 Septem
ber 15, 2020 at Kobenhavns Universitets Bibliotek.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-033720 on 20 August 2020. Downloaded from 
2 Winkel P, et al. BMJ Open 2020;10:e033720. doi:10.1136/bmjopen-2019-033720
Open access 
vascular stiffness and the presence of unstable atheroscle-
rotic plaques; (5) pregnancy- associated plasma protein 
A (PAPP- A), a marker of vulnerable plaques in coronary 
arteries; (6) cathepsin- B and (7) cathepsin- S, a group 
of proteinases that have been suggested to be causally 
involved in the different stages of the atherosclerotic 
process; (8) endostatin, an endogenous angiogenesis 
inhibitor suggested to mirror an increased neovascu-
larisation induced by vascular or myocardial ischaemia; 
the soluble receptors, (9) soluble tumour necrosis factor 
receptor 1 (sTNFR1) and (10) soluble TNF receptor 2 
(sTNFR2), suggested to portray information about a 
systemic inflammatory state that is independent of other 
more established inflammatory markers; (11) calpro-
tectin and (12) neutrophil gelatinase- associated lipocalin 
(NGAL), both released from neutrophils when the cells 
are activated. Circulating levels of neutrophils and their 
activation products have been shown to be markers for 
plaque instability in both primary and secondary preven-
tion of CV diseases.
All of these have been claimed to add some prog-
nostic information in patients with stable coronary artery 
disease. Our group has tested the individual importance 
of many of these biomarkers, and in many studies statis-
tical inference supports the view that biomarkers may 
improve the prediction.5–12
Our objectives were to clarify: (1) which of these newer 
biomarkers maintain their prognostic importance if all of 
them were simultaneously available and were combined 
with the routinely available clinical and laboratory infor-
mation, and (2) what would then be their relative practical 
contribution if they were added to the ‘standard predic-
tors’ such as age, smoking, plasma lipids, etc. In accor-
dance with our published statistical analysis plan,2 our 
analysis focusses on all- cause death and on a composite 
outcome comprising AMI, unstable angina pectoris 
(UAP), cerebrovascular disease (CeVD) and death.
MATERIALS
2 The patients
The study population is the placebo patients from the 
CLARICOR study.3 4 Patients aged 18–85 years, from 
the Copenhagen area, who had a discharge diagnosis of 
myocardial infarction or angina pectoris during 1993–
1999 and were alive in August 1999 were invited by letter 
for an interview and a 14- day trial of clarithromycin versus 
placebo.3 4 Out of the 4372 who were randomised during 
October 1999 through April 2000, 2200 were in the 
placebo group.
The main results of the trial were that clarithromycin 
increased the risk of CV as well as all- cause death.13–15 
Therefore, we here focus on the placebo group.
For the CLARICOR trial, only patients who were in a 
stable state of their coronary heart disease were selected. 
Thus, patients were excluded if they fulfilled one or more 
of the following conditions: (1) had suffered from AMI or 
UAP within the previous 3 months; (2) had intracoronary 
interventions within the previous 6 months; (3) had 
impaired renal function; (4) had hepatic dysfunction; 
(5) had congestive heart failure (New York Heart Asso-
ciation IV classification of heart failure); (6) had active 
malignancy; (7) were without capacity to manage own 
affairs; (8) were breast feeding and (9) were possibly 
pregnant.
Of the 2200 participants one had garbled study data, 
and further 201 had one or more missing biomarker 
measurements (see below), leaving 1998 participants for 
the present analysis. Only 15 of these were lost track of 
due to emigration or disappearance.
2 The predictors
Information on smoking status, current medication, 
known hypertension, diabetes, sex, age and myocardial 
infarction at index hospitalisation or UAP was obtained 
from the local hospital files and patient interviews.
3 Biochemical measurements on serum collected at enrolment 
visit
Biochemical data were obtained from analysis of serum 
specimens sampled at inclusion of the patients and 
stored at   - 80ºC. The quantities measured include lipo-
proteins,16 high- sensitivity- C- reactive- protein/mg/L7 and 
glomerular filtration rate/mL/min using creatinine.17 
These quantities together with the variables mentioned 
under predictors above are those collectively referred to 
as 'standard predictors'.
Biomarkers included as newer biomarkers were YKL40/
µg/L8; hs- cTnT/ng/L9; binary pregnancy associated 
plasma protein- A (binary- PAPP- A), which is coded as 1 
if PAPP- A was ≥4 mIU/L or 0 otherwise10; pro- BNP/ng/
L9; cathepsin- B/µg/L6 18; endostatin/ng/mL19; cathep-
sin- S/µg/L6 20; sTNFR1/pg/mL and sTNFR2/pg/mL5 21; 
NGAL/ng/L22; calprotectin/mg/L11 and OPG/ng/L.12 
Due to storage problems some marker data are missing 
on some patients.
2 The outcomes
Initial follow- up of the patients lasted for approximately 
2.6 years, during which outcomes were collected through 
hospital and death registries and assessed by an adjudi-
cation committee.4 Corresponding register data later 
produced similar results.23 24 The adjudicated outcomes 
were therefore replaced and augmented by register 
outcomes to cover up to 10 years±3 months of follow- up. 
Last register follow- up was 31 December 2009. The public 
registers have an almost 100% coverage and the quality 
of these is described elsewhere.25 26 The algorithm used 
to get from the International Statistical Classification of 
Diseases used in the national registries to the events of 
the composite outcome is described in detail previously.13
We assessed (1) the time from randomisation to all- 
cause death and (2) the time from randomisation until 
the first occurrence of one of the following outcomes: 
AMI, UAP, CeVD or all- cause death.
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1 METHODS
2 Statistical analysis
The statistical principles and techniques used have previ-
ously been published.1 2 While our previous publication1 
dealt with the prognostic impact of the ‘standard predic-
tors’, we here use the same techniques to quantify the 
effect of adding biomarker information to the ‘standard 
predictors’.
We used Cox regressions (SAS V.9.4), where all analyses 
that included covariates were stratified by centre. The 
assumption of proportional hazards over time covering 
all covariates included in a Cox analysis and the chosen 
functional form of quantitative covariates was tested 
using cumulative sums of martingale- based residuals over 
follow- up time and/or covariate values.27
We also analysed data using a parametric, accelerated 
failure- time model using the generalised gamma model 
of error.28 A significance level of 0.01 was used to pinpoint 
empirical trends worthy of note. The logarithms of the 
present text are natural logarithms, so whenever the 
predictor is a log(serum concentration/unit), the HR is 
the factor by which the hazard increases when the loga-
rithm increases by 1, that is, when the concentration 
increases by a factor e=2.72.
Biomarkers with an HR with p value  ≥ 0.01 when used 
alone as covariate as well as when used in combina-
tion with the ‘standard predictors’ were excluded from 
further analyses. The remaining biomarkers were consid-
ered prognostic.
Assessment of the practical impact of using the set of 
newer biomarkers was obtained by comparing the per 
cent correct predictions obtained when the standard 
predictors were used alone with the percentage obtained 
when they were combined with the novel biomarkers 
using the method described earlier.1
Second, we report the areas under the receiver oper-
ating characteristics (ROCs), also known as area under 
the curves (AUCs) or C- indices, which one obtains when 
the Cox- Breslow risk estimates are matched against the 
events seen in the time window 0- to-9 years. The much- 
used binary (event vs no event) C- index is the concor-
dance rate between risks and outcomes. It shows how 
frequently an event participant has a poorer prediction 
score than a non- event participant. In order to reward 
correct prediction of time of event, we further report 
Harrell’s ‘dynamic’ (or ‘overall’) C- index.29 30 It shows 
how frequently an earlier- event participant has a poorer 
prediction than a later- or- never- event participant. In 
other words, it is the concordance between risk score and 
event time. It is calculated across all pairs of participants 
where the time order of the pair is deducible from the 
9- year data window.
It is noted that in the ROC analysis it was not possible to 
add two time- dependent covariates, which were needed 
to compensate for the fact that both age and log(OPG/
ng/L) violated the assumption of proportional hazard. 
However, the output obtainable from the SAS procedure 
did not allow the inclusion of time- dependent covariates.
2 Patient and public involvement
There was no direct patient involvement in the design of 
the trial, but the majority of the investigators had daily 
contact with patients comparable to those included in 
the trial and therefore knew their needs and preferences 
well. Moreover, there were patient representatives as part 
of the regional ethics committee approving the trial.
1 RESULTS
Table 1 presents an overview of the covariates expected to 
be available from patients with stable CV disease during 
clinical routine work (‘standard predictors’) plus the 12 
newer biochemical quantities under investigation. The 
data revealed that at 3 years, 2073 (94.2%) were still 
alive and 1826 (83.0%) had not yet suffered a composite 
outcome. At 6 years, 1758 (79.9%) were still alive and 1261 
(57.3%) had not yet suffered a composite outcome. At 9 
years, the numbers were 1487 (67.6%) and 969 (44.0%).
Out of 2099 placebo patients, 1998 had complete 
biochemical data. As Little’s test31 had p=0.49, suggesting 
that the values were missing completely at random, we 
used complete case analyses in the following.
Two of the 12 newer biomarkers (log(Calprotectin) 
and log(Cathepsin- S)) did not contribute significantly 
(p>0.01) to the prediction of any of the two outcomes, 
neither when used in combination with the ‘standard 
predictors’ nor when used alone (see online supplemen-
tary tables 1S and 2S). They were therefore removed from 
the subsequent analyses. In the analysis of log(OPG/
ng/L), we found that the assumption of proportional 
hazard was significantly violated. This was remedied 
when we included the time- dependent covariate log 
(OPG/ng/L)*time/year in the subsequent regression 
equation (see online supplementary table 2S). The 
latter equation now included the ‘standard predictors’, 
plus the remaining 10 newer biomarkers and the above- 
mentioned time- dependent covariates. It appears from 
online supplementary table 2S that only log(pro- BNP/
ng/L), log(hs- cTnT/ng/L) and log(OPG/ng/L)*time/
year contributed significantly to the prediction.
Table 2 (see also online supplementary tables 3S and 4S) 
compares the number and percentages of correct predic-
tions between various prediction models. In each model, 
predictions were made at 3, 6 and 9 years for each of the 
two outcomes (death and the composite). Model 1 shows 
the results obtained using a model void of covariates; 
79.8% of the predictions were correct for the outcome 
death and 63.2% for the composite outcome. Model 2 
shows the results obtained when model 1 was augmented 
by the ‘standard predictors’. Now the per cent correct 
predictions have been improved by 83.3%–79.8%=3.5% 
for the outcome death and 68.4%–63.2%=5.2% for the 
composite outcome. When model 2 was improved by 
adding the 10 newer biomarkers, the additional gain 
in correct predictions amounted to 1.4% for death and 
1.3% for the composite outcome.
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Using the parametric model in place of the Cox model, 
we obtained quite similar results (see online supplemen-
tary tables 3S and 4S and online supplementary figure 
1S A–B). The same was true if we only included log(-
pro- BNP/ng/L), log(hs- cTnT/ng/L) and log(OPG/
ng/L) instead of all 10 biomarkers when the Cox model 
was used (see online supplementary tables 3S and 4S).
Table 3 summarises the ROC analyses. For prediction 
of the composite outcome (yes/no), the area under the 
ROC increases from 0.711 to 0.732 when the 10 novel 
biomarkers are added to the ‘standard predictors’, but 
almost all the marker information is contained in log(hs- 
cTnT/ng/L) and log(pro- BNP/ng/L) (AUC=0.730). 
The ‘dynamic’ C- index values are smaller as prediction 
of event times is more difficult, but the gains are similar. 
All- cause death shows the same general pattern.
1 DISCUSSION
In this study, we assessed the combined value of 12 newer 
biomarkers not routinely used in clinical work to predict 
all- cause death and a composite outcome (AMI, UAP, 
CeVD or all- cause death). We used a cut value of predicted 
risk=0.5 to separate correct predictions of the observed 
patient status from incorrect ones. When we combined 
the biomarkers with the ‘standard predictors’ routinely 
available for a general practitioner when he/she meets 
a patient with stable coronary artery disease (CAD), 
84.7% of the survival status were correctly predicted. In 
case of the composite outcome the number was 68.4%. 
In both cases, the combined contribution of the newer 
biomarkers amounted to <1.5%.
Our patients resemble those of The Prospective 
Observational Longitudinal Registry of Patients with 
Stable Coronary Heart Disease (CLARIFY) study,32 
which enrolled 20 291 patients. The CLARIFY patients 
had been observed with a median of 24.1 months. 
However, enrolment took place 10 years later than in 
the CLARICOR trial and the incidence of CV deaths 
or myocardial infarctions in these patients was consid-
erably lower,32 probably reflecting improved quality of 
treatment and more frequent statin treatment in the 
CLARIFY patients (84% compared with only 41% in the 
CLARICOR material). So, the age of our material is a 
weakness.
In our present study, we are using our data to develop 
a prediction model. Then we evaluate the performance 
using the same data that we used to develop the model. 
Clearly, this is bound to produce overly optimistic results 
compared with testing our model using independent data. 
But we argue that the aim of this study was not to present 
a prediction model but to assess the newer biomarkers’ 
contribution to model performance when added on top 
of routinely available clinical and laboratory data. There-
fore, if tested on independent data, the contribution of 
the newer biomarkers to prognosis of patients with stable 
CAD are likely going to be worse than observed here.
Table 1 Distributions of demographics, previous history, 
current medication, standard biochemical predictors and 
newer biochemical predictors in 2199 placebo receiving 
patients from the CLARICOR trial
Quantity Distribution
Demographics and previous history
  Sex (male) N (%) 1518 (69.0%)
  Age/year mean (SD) 65.2 (10.4)
  Smoking status N (%)
   Smokers 753 (34.2%)
   Ex- smokers 1011 (46.0%)
   Never smoked 435 (19.8%)
  Hypertension N (%) 883 (40.2%)
  Diabetes N (%) 337 (15.3%)
  Previous AMI N (%) 1494 (67.9%)
Current medication
  Aspirin N (%) 1937 (88.1%)
  Beta- blocker N (%) 681 (31.0%)
  Calcium- antagonist N (%) 772 (35.1%)
  ACE- inhibitor N (%) 577 (26.3%)
  Long- lasting nitrate N (%) 457 (20.8%)
  Diuretics N (%) 773 (35.2%)
  Digoxin N (%) 126 (5.7%)
  Statins N (%) 904 (41.1%)
  Anti- arrhythmic drugs N (%) 51 (2.3%)
Standard biochemical predictors
  log(CRP/mg/L) mean (SD) N*   1.03 (1.12) 2159
  ApoA1/mg/dL mean (SD) N 1.70 (0.34) 2076
  log(ApoB/mg/dL) mean (SD) N 0.16 (0.27) 2075
  Chol- HDL/mmol/L mean (SD) N 1.02 (0.32) 2074
  Chol- LDL/mmol/L mean (SD) N 2.56 (0.72) 2079
  log(Cholesterol/mmol/L) mean (SD) N 1.73 (0.20) 2075
  log(Triglyceride/mmol/L) mean (SD) N 0.73 (0.53) 2078
  Glomerular filtration rate (GFR/mL/min) 
mean (SD) N
71.8 (19.2) 2079
Newer biochemical predictors
  log(pro- BNP/ng/L) mean (SD) N 5.26 (1.37) 2149
  log(hs- cTnT/ng/L) mean (SD) N 2.01 (0.78) 2111
  log(Endostatin/ng/mL) mean (SD) N 10.3 (0.34) 2121
  log(OPG)/ng/L) mean (SD) N 7.49 (0.40) 2108
  log(TNFR1/pg/mL) mean (SD) N 7.40 (0.40) 2120
  log(TNFR2/pg/mL) mean (SD) N 8.54 (0.33) 2120
  PAPP- A ≥4 mIU/L count (%) N 288 (13.1%) 2140
  log(YKL40/µg/L) mean (SD) N 4.75 (0.66) 2163
  log(NGAL/ng/L) mean (SD) N 11.6 (0.46) 2121
  log(Cathepsin- B/µg/L) mean (SD) N 10.6 (0.45) 2120
  log(Cathepsin- S/µg/L) mean (SD) N 9.48 (0.27) 2121
  log(Calprotectin/mg/L) mean (SD) N 0.77 (0.59) 2086
*The value of N varies because the laboratory tests have missing values (mostly due to 
storage problems). log: natural logarithm.
AMI, acute myocardial infarction; CRP, C reactive protein; HDL, high- density 
lipoprotein; hs- cTnT, high- sensitive assay cardiac troponin T; LDL, low- density 
lipoprotein; NGAL, neutrophil gelatinase- associated lipocalin; OPG, osteoprotegerin; 
PAPP- A, pregnancy- associated plasma protein A; pro- BNP, serum N- terminal pro- B- 
type natriuretic peptide; TNFR1, tumour necrosis factor receptor 1; TNFR2, tumour 
necrosis factor receptor 1.
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2 Methodology
Regarding our methodology, the performance statistics 
reported here are minimal, but they suffice to show that 
the results are meagre. Prediction at 3, 6 and 9 years 
covers the follow- up as well as a sophisticated integral 
over continuous time.
2 Strengths
The strengths of the CLARICOR trial are the size of the 
patient population, the long duration of follow- up, few 
losses to follow- up (1%), the ethnic homogeneity of the 
patient population (most being Caucasians), rarity of 
missing values, with focus on an operationally defined, 
homogeneous and relevant patient category. The design 
implies that the patients are sampled at random, presum-
ably uneventful, time points during their stable state (as 
defined by the CLARICOR trial).
2 Limitations
Among those 7586 patients who declined our invitation 
to visit a cardiology centre, many must have been eligible 
for the CLARICOR trial, and we do not know how they 
looked and fared. With a response rate about 50%, the 
cohort could represent a prognostic elite if responders 
were mostly mobile and health- conscious patients. So, 
selection bias cannot be excluded.
Furthermore, users of these data should remain aware 
of one feature: patients if any who became eligible for the 
CLARICOR trial during the period 1993 to 1999 and then 
died before August 1999 are absent. Thus, our data do not 
represent patients as they enter a stable disease state (as 
delimited by CLARICOR exclusion criteria); instead, they 
may be regarded as community patients (subject to some 
self- selection) seen by their physician or at an outpatient 
clinic on a random date during their stable state.
The patients recruited for the CLARICOR trial were 
diagnosed with CAD about 20 years ago. Because of the 
developments in treatment and rehabilitation, there 
has been a very significant and gradual improvement 
in the prognosis of such patients as shown in national 
data.33 Given these uncertainties, prognostic findings 
in the CLARICOR cohort may not be directly applied 
to present- day patients. However, the overall, somewhat 
disappointing, picture presented by the predictive perfor-
mance of standard1 and newer biochemical predictors 
studied 10–20 years ago would hardly be much different 
if studied today.
Potential weaknesses of the present cohort within the 
context of prognostication of patients with stable CAD 
as here defined include the fact that only questionnaire 
data were collected at randomisation. No data are avail-
able concerning left ventricle function, body mass index, 
blood pressure and general health. These shortcomings 
are mitigated by the fact that, by design, the present study 
Table 3 C- indices
Binary 
outcome C 
(AUC) Dynamic C
Observed 
(predicted)* Observed†
Composite outcome‡ (1115 events)
  SP only 0.711 (0.707) 0.640
  The 10 newer markers and SP 0.732 (0.732) 0.657
  log(hs- cTnT/ng/L)+log(pro- 
BNP/ng/L)+SP
0.730 (0.730) 0.656
All- cause death (644 deaths)
  SP only 0.792 (0.793) 0.737
  The 10 newer markers and SP 0.824 (0.816) 0.765
  log(hs- cTnT/ng/L)+log(pro- 
BNP/ng/L)+SP
0.821 (0.813) 0.762
Cox model estimates applied to the 0–9 years follow- up window 
(n=1998).
*The ‘observed’ AUCs summarise a ROC plot of cumulative 
events against cumulative non- events, with cumulation from 
large to small estimated risks. The corresponding ‘predicted’ 
AUC cumulates the predicted risks instead. Discrepancies 
between the two curves would suggest a model failure 
(calibration problems). The curves (not shown) were practically 
identical.
†Analogous concordance rate between time to event and 
predicted risk.
‡Composite outcome: first occurrence of acute myocardial 
infarction, unstable angina pectoris, cerebrovascular disease or 
death (table 1.
AUC, area under the curve; hs- cTnT, high- sensitive assay 
cardiac troponin T; ROC, receiver operating characteristics; SP, 
standard predictors.
Table 2 The two outcomes (1) all- cause death and (2) the composite outcome of AMI, UAP, CeVD or all- cause death were 
studied
Model and covariates included in model
Total number of 
predictions made 
per outcome
Number and per cent of correct predictions of events
All- cause death
N (%)
Composite of AMI, UAP,
CeVD or all- cause death N (%)
Model 1: Cox model void of covariates 5972 4768 (79.8) 3773 (63.2)
Model 2: Cox model with
‘Standard predictors (SP)’ added to model
5972 4977 (83.3) 4084 (68.4)
Model 3: Cox model with
SP+10 newer biomarkers added to model
5972 5056 (84.7) 4165 (69.9)
AMI, acute myocardial infarction; CeVD, cerebrovascular disease; UAP, unstable angina pectoris.
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sees the patient in a situation where (s)he visits a physi-
cian for reasons unrelated to the coronary disease, as 
already stressed. In such situations, counselling and deci-
sions must typically be made without access to echocardi-
ography or other special investigations. Furthermore, if 
this information had been available, the prognostic gain 
we study would probably have been still poorer. More-
over, we included age, sex, hypertension, prior myocar-
dial infarction, information about current medication 
which has previously been shown to be a fair replacement 
for prognostication instead of left ventricular ejection 
fraction.34
It is noted that the patients studied by us were all in a 
stable state of their disease, without cardiac complaints. 
Therefore, one should not conclude from this study that 
the biomarkers studied here may not be useful in many 
other clinical contexts, although biomarkers have been 
shown to of modest help in evaluating CV risk assessment 
in asymptomatic people not suffering from CAD.35
1 CONCLUSIONS
In the present clinical context, the contribution of the 12 
biomarkers not yet used in clinical routine work proved 
to be minimal. Furthermore, of the 10 statistically prom-
ising novel biomarkers all could be replaced by hs- cTnT 
and pro- BNP, possibly supplemented by OPG.
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